Characterization of 107 Genomic DNA Reference Materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1

Abstract

Pharmacogenetic testing is becoming more common; however, very few quality control and other reference materials that cover alleles commonly included in such assays are currently available. To address these needs, the Centers for Disease Control and Prevention's Genetic Testing Reference Material Coordination Program, in collaboration with members of the pharmacogenetic testing community and the Coriell Cell Repositories, have characterized a panel of 107 genomic DNA reference materials for five loci (CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1) that are commonly included in pharmacogenetic testing panels and proficiency testing surveys. Genomic DNA from publicly available cell lines was sent to volunteer laboratories for genotyping. Each sample was tested in three to six laboratories using a variety of commercially available or laboratory-developed platforms. The results were consistent among laboratories, with differences in allele assignments largely related to the manufacturer's assay design and variable nomenclature, especially for CYP2D6. The alleles included in the assay platforms varied, but most were identified in the set of 107 DNA samples. Nine additional pharmacogenetic loci (CYP4F2, EPHX1, ABCB1, HLAB, KIF6, CYP3A4, CYP3A5, TPMT, and DPD) were also tested. These samples are publicly available from Coriell and will be useful for quality assurance, proficiency testing, test development, and research. Many laboratories are testing for pharmacogenetic (PGx) markers, common genetic variants that are usually considered only when a patient is likely to be exposed to a Accepted for publication June 21, 2010. R.B., A.E.-B., C.S., A.V., and M.Z. are employees of AutoGenomics (manufacturer of several pharmacogenetic assays used in this study); M.B., A.B., and K.M. are employees of Quest Diagnostics Inc.; J.M. is an employee of Idaho Technology (manufacturer of the reagents used to genotype CYP2C9 and VKORC1 loci for this project);

Report of New Haplotype for ABCC2 Gene

“…10 An additional 50 anonymous DNA samples were obtained from the Indiana BioBank (Indianapolis, IN). Three anonymized whole-blood and matched saliva samples from unrelated individuals were also obtained.…”

The CYP4502D6 *4 and *6 alleles are the molecular genetic markers for drug response: implications in colchicine non-responder FMF patients

“…The activity of many drugs depends on their interaction with enzymes of the CYP450 system (Evans and Relling 2004;Landino et al 2011). CYP2D6 is the best-characterised polymorphic CYP gene, with more than 80 relevant alleles identified on the chromosome 22q13.1 (Pratt et al 2010). Polymorphisms in CYP2D6 result in poor metabolism (PM), intermediate metabolism (IM), extensive metabolism (EM) and ultrarapid metabolism (UM) of drugs (Zanger et al 2001).…”

Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy

“…In conjunction with the Association for Molecular Pathology and the College of American Pathologists (CAP), the Genetic Testing Reference Materials Coordination Program coordinated the characterization of 107 DNA samples for clinically relevant polymorphisms for pharmacogenetic loci including CYP2D6. 34 Other loci that have been characterized include CYP450 (2C9, 2C19, 3A4, and 3A5) …”